Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Polymorphous light eruption

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Polymorphous light eruption. Displaying page 1 of 1.
    EudraCT Number: 2008-000626-39 Sponsor Protocol Number: Calcipotriol_PLD_1.0 Start Date*: 2008-08-28
    Sponsor Name:Medizinische Universität Graz
    Full Title: Calcipotriol zur Prävention der Polymorphen Lichtdermatose
    Medical condition: Polymorphic light eruption
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036087 Polymorphic light eruption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005321-40 Sponsor Protocol Number: CUV015 Start Date*: 2007-01-19
    Sponsor Name:Clinuvel Pharmaceuticals Limited
    Full Title: A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of CUV1647 in patients suffering from polymorphic light eruption (PLE).
    Medical condition: Polymorphic light eruption (PLE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036087 Polymorphic light eruption PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) AT (Completed) BE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010843-15 Sponsor Protocol Number: CUV026 Start Date*: 2009-10-09
    Sponsor Name:Clinuvel Pharmaceuticals Limited
    Full Title: A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light er...
    Medical condition: Polymorphic light eruption (PLE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036087 Polymorphic light eruption PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017359-92 Sponsor Protocol Number: CUV032 Start Date*: 2010-05-18
    Sponsor Name:Clinuvel Pharmaceuticals Limited
    Full Title: A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from pol...
    Medical condition: Polymorphic light eruption (PLE)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036087 Polymorphic light eruption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004074-93 Sponsor Protocol Number: EP005 Start Date*: 2005-03-01
    Sponsor Name:EpiTan Limited
    Full Title: A Pilot, Phase II, Open, Controlled Study to Evaluate the Safety, Tolerability and Efficacy of a Subcutaneous Implant of Melanotan in Patients Suffering from Recurrent Polymorphous Light Eruption.
    Medical condition: Polymorphous Light Eruption (PMLE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001241-14 Sponsor Protocol Number: V00096 CR 201 Start Date*: 2004-11-12
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: Efficacy of topic RV3131A-HC3221 in the prevention of polymorphic light eruption
    Medical condition: Polymorphic Light Eruption (PMLE)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 19:45:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA